<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000385</url>
  </required_header>
  <id_info>
    <org_study_id>R29MH057093</org_study_id>
    <secondary_id>R29MH057093</secondary_id>
    <secondary_id>DSIR CT-M</secondary_id>
    <nct_id>NCT00000385</nct_id>
  </id_info>
  <brief_title>Long-Term Lithium Treatment for Aggressive Conduct Disorder</brief_title>
  <official_title>Long-Term Lithium for Aggressive Conduct Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Drexel University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Drexel University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the long-term effects of lithium used to treat children and&#xD;
      adolescents with aggressive conduct disorder (severe aggression).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Psychotherapeutic agents are often administered without sufficient testing to children and&#xD;
      adolescents, often on a long-term basis, to reduce aggression. Many pressures, including&#xD;
      managed care, will increase the utilization of pharmacotherapy in the outpatient setting to&#xD;
      treat serious problems. Lithium is the most promising agent for the treatment of aggression&#xD;
      in children and adolescents. However, it has not been shown that lithium is an effective&#xD;
      treatment for these patients in the outpatient (non-hospital) setting, or on a long-term&#xD;
      basis. The purpose of this study is to examine the long-term effects of lithium used to treat&#xD;
      children and adolescents with aggressive conduct disorder (severe aggression).&#xD;
&#xD;
      The proposed study is a two-phased clinical trial of lithium for the treatment of aggression&#xD;
      in conduct disorder. Both phases are double-blind and placebo-controlled with randomization&#xD;
      and employ a parallel groups design. Phase 1 contains a short-term 8-week controlled trial,&#xD;
      with twice as many subjects randomized to lithium as placebo, increasing the pool of&#xD;
      potential lithium responders to continue to Phase 2. In Phase 2, lithium responders from&#xD;
      Phase 1 enter a 6-month long-term controlled trial. Every attempt is made to define&#xD;
      responders to lithium.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1997</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">December 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overt Aggression Scale-Modified</measure>
    <time_frame>Weekly in short term phase, Monthly in long-term phase</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Global Impressions-Improvement Item</measure>
    <time_frame>Weekly in short term phase, Monthly in long-term phase</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Children's Psychiatric Rating Scale-Selected Items</measure>
    <time_frame>Weekly in short term phase, Monthly in long-term phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IOWA</measure>
    <time_frame>Weekly in short term phase, Monthly in long-term phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOTES</measure>
    <time_frame>Weekly in short term phase, Monthly in long-term phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TESS</measure>
    <time_frame>Weekly in short term phase, Monthly in long-term phase</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Conduct Disorder</condition>
  <condition>Aggression</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lithium 600 mg to 2700 mg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium</intervention_name>
    <description>Lithium 600 mg to 2700 mg per day</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females&#xD;
&#xD;
          2. Ages between 9 and 17 years.&#xD;
&#xD;
          3. Conduct disorder according to DSM-IV (As rated on the DICA-IV).&#xD;
&#xD;
          4. The aggression criterion at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Mental Retardation.&#xD;
&#xD;
          2. Pervasive Developmental Disorder(s).&#xD;
&#xD;
          3. Major Depressive Disorder or Dysthymic Disorder.&#xD;
&#xD;
          4. Bipolar Disorder.&#xD;
&#xD;
          5. Psychotic Disorder (including Schizophreniform Disorder and Schizophrenia).&#xD;
&#xD;
          6. Major medical problem such as cardiac, renal, and thyroid diseases, or seizure&#xD;
             disorder.&#xD;
&#xD;
          7. History of psychoactive medication in the previous 2 weeks.&#xD;
&#xD;
          8. Current Pregnancy in females.&#xD;
&#xD;
          9. History of Substance Dependence in the past month.&#xD;
&#xD;
         10. Prior to the proposed study, a history of lithium treatment with serum lithium levels&#xD;
             of 0.4 mEq/L or higher for a cumulative period of greater than 10 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard P. Malone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Drexel University College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Drexel University College of Medicine at Friends Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>November 2, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 1999</study_first_posted>
  <last_update_submitted>November 25, 2013</last_update_submitted>
  <last_update_submitted_qc>November 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2013</last_update_posted>
  <responsible_party>
    <name_title>Richard P. Malone, MD</name_title>
    <organization>Drexel University College of Medicine</organization>
  </responsible_party>
  <keyword>Aggressive conduct disorder</keyword>
  <keyword>Adolescence</keyword>
  <keyword>Child</keyword>
  <keyword>Conduct Disorder</keyword>
  <keyword>Female</keyword>
  <keyword>Lithium</keyword>
  <keyword>Male</keyword>
  <keyword>Placebos</keyword>
  <keyword>Conduct Disorder -- *drug therapy</keyword>
  <keyword>Lithium -- *therapeutic use</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Aggression</mesh_term>
    <mesh_term>Conduct Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lithium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

